WEHI is where the world’s brightest minds collaborate and innovate to make discoveries that will help us to live healthier for longer.
We bring together people with different skills and experience who are committed to long-term discovery. Our medical researchers have been serving the community for more than 100 years. We know that we can achieve better things bringing together diverse teams who work together for 10, 20 or even 50 years to tackle the big issues.
We are brighter because of our collaborations with hospitals, universities, research institutes and industry, and the support of our community, including philanthropists, donors and bequestors, alumni and consumers.
WEHI is a place where people are able to shine. People who are inquisitive, who are committed, who are passionate. People who want to make a difference. And we are committed to ensuring they have the tools to flourish, personally and professionally.
Our teams of researchers are committed to solving the most complex health problems, making transformative discoveries for cancer, infectious and immune diseases, developmental disorders and healthy ageing.
Cancer – understanding the basic processes that are disrupted to generate cancer cells, and how these can be targeted to treat disease
Immune health and infection – discovering how the body fights infection, and how errors in the immune system lead to disease
Development and healthy ageing – studying how the biological foundations laid down during gestation and childhood affect development, and how our longer life expectancy presents new challenges for our ageing population
New medicines and advanced technologies – a powerful hub for cutting-edge technologies underpinning biomedical discoveries and for the translation of these discoveries into new medicines and diagnostics.
Computational biology – developing and applying new tools to analyse the genomes of disease-causing parasites, as well as better understanding the immune system and genetic drivers of cancer.
Misty Jenkins, PhD
Our research focusses on a type of adoptive T cell immunotherapy called Chimeric Antigen Receptor T cell (CAR T cell) therapy. CAR T cells are engineered from a patient’s own T cell, to recognise and attack cancer cells. We are designing and testing CAR T cells directed against adult and paediatric
Melissa Davis, PhD
The Davis Laboratory studies the regulatory networks that control the behaviour of cells in normal and cancerous tissues. We approach these questions with a suite of computational techniques that include classical bioinformatics methods, knowledge-based modelling, machine learning, and network analy